MOUNTAIN VIEW, Calif., Oct. 2, 2012 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today preclinical results for CCX872, the Company's next-generation, orally bioavailable inhibitor of the chemokine receptor known as CCR2. The findings showed that treatment with CCX872 improved multiple parameters of renal function in an in vivo model of diabetic nephropathy. The data were reported in an oral presentation titled, "CCR2 Inhibition Improves Renal Function in Diabetic BTBR ob/ob Mice," at the 48th Annual Meeting of the European Association for the Study of Diabetes (EASD) taking place in Berlin.
CCX872 is a next generation CCR2 inhibitor which is currently in advanced preclinical development for the treatment of metabolic disease. CCX140, the Company's lead independent CCR2 inhibitor, and CCX872 are wholly owned by ChemoCentryx. CCX140 has successfully completed a Phase II clinical trial in type 2 diabetics as a gateway study to initiate clinical testing in patients with diabetic nephropathy. CCX140 is being evaluated in two ongoing Phase II studies in the latter patient population, with data expected to report in 2013.
"Earlier this year, we reported we would advance CCX872 or a CCR9 next-generation drug candidate into the clinic in 2012, and we remain on track to meet this milestone," stated Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. "Our strategy for advancing both a lead and backup drug candidate in our independent program targeting CCR2 serves to both developmentally de-risk the program and strengthen it from a business development perspective as we seek to partner Ex-North American rights for this program."
CCX872 In Vivo Data
Building on previous reports of the benefits induced by CCX872 in various mouse models of diabetic nephropathy, such as improvements in albuminuria, serum markers of renal function, and renal inflammation and remodeling, data reported at EASD today evaluated CCX872 in a genetic mouse model of diabetic nephropathy considered by those in the field to emulate key aspects of the human disease. In this model, CCX872 produced a pronounced improvement in albuminuria and histological measures of kidney damage, such as glomerular basement membrane thickening.
Dr. Schall commented, "We are pleased that we have the opportunity to share our findings around the role of CCR2 inhibition in chronic kidney disease with the medical community at EASD. These results – demonstrating modulation of multiple disease markers independently of anti-glycemic activity – add to the volume of scientific evidence we and others have already generated, validating the role of CCR2 inhibition in the treatment of chronic kidney disease."
ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. The Company's most advanced drug candidate, vercirnon (also known as Traficet-EN, CCX282 or GSK1605786), a specific CCR9 inhibitor, completed a multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease, where it demonstrated the ability to induce a clinical response and to maintain clinical remission, and is now in Phase III clinical development. The Company's lead independent drug candidate, CCX140, a CCR2 inhibitor, has been shown to be safe and well tolerated while demonstrating clinical activity on glycemic indices in a Phase II clinical trial in type 2 diabetics, and is now in Phase II clinical development for the treatment of diabetic nephropathy. Other clinical programs include CCX354 (also known as GSK2941266), a CCR1 inhibitor which successfully completed a Phase II clinical trial for the treatment of rheumatoid arthritis, and CCX168, a C5aR inhibitor in Phase II clinical development for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. ChemoCentryx also has several programs in advanced preclinical development.
ChemoCentryx cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "may," "could," "will," "would," "should," "expect," "plan," "anticipate," "believe," "estimate," "intend," "predict," "seek," "contemplate," "potential" or "continue" or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. The inclusion of forward-looking statements should not be regarded as a representation by ChemoCentryx that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the ChemoCentryx business and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and ChemoCentryx undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in ChemoCentryx's periodic reports filed with the Securities and Exchange Commission ("SEC"), including ChemoCentryx's Annual Report on Form 10-K for the year ended December 31, 2011 and Quarterly Report on Form 10-Q for the three-month period ended June 30, 2012, which are available from the SEC's website (www.sec.gov) and on ChemoCentryx's website (www.ChemoCentryx.com) under the heading "Investors." All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
CCXI - G
CONTACT: Susan M. Kanaya Senior Vice President, Finance and Chief Financial Officer or Markus J. Cappel, Ph.D. Chief Business Officer 650-210-2900 firstname.lastname@example.org Burns McClellan Media Inquiries Justin Jackson 212-213-0006 email@example.com Maroussia Czarny firstname.lastname@example.org